Ann Surg Treat Res.  2022 Jul;103(1):12-18. 10.4174/astr.2022.103.1.12.

Analysis of the cause and management of persistent laboratory abnormalities occurring after the surgical treatment of primary hyperparathyroidism

• Lee JE
• Hong N
• Kim JK
• Lee CR
• Kang SW
• Jeong JJ
• Nam KH
• Chung WY
• Rhee Y

• KMID: 2531143
• DOI: http://doi.org/10.4174/astr.2022.103.1.12

Abstract

Purpose
The surgical success rate for primary hyperparathyroidism (PHPT) is currently 95%–98%. However, 3%–24% of patients show persistently elevated (Pe) parathyroid hormone (PTH) levels after parathyroidectomy (PTX). This singlecenter retrospective study aimed to compare the outcomes of patients with normal PTH and PePTH levels after successful PTX and to identify the factors associated with PePTH.
Methods
The normal group, defined as patients with normal serum calcium and PTH levels immediately after PTX, was compared with the PePTH group (patients with normal or low serum calcium and increased serum PTH levels up to 6 months postoperatively) to determine the causes of disease in the PePTH group.
Results
There were no significant differences in age, sex, or preoperative estimated glomerular filtration rate between the normal PTH group (333 of 364, 91.5%) and the PePTH group (31 of 364, 8.5%). However, there were significant differences in preoperative 25-hydroxyvitamin D (17.9 and 11.8 ng/mL, respectively; P = 0.003) and PTH levels (125.5 and 212.4 pg/mL, respectively; P < 0.001) between the 2 groups. Among the 31 cases of the PePTH group, 18 were attributed to vitamin D deficiency.
Conclusion
Preoperative vitamin D deficiency is a predictive factor for PePTH. Therefore, preoperative administration of vitamin D supplements may reduce the probability of postoperative disease persistence. Patients with temporary laboratory abnormalities within 6 months after successful PTX should be monitored, and appropriate vitamin D and calcium supplementation may reduce the effort and cost of various examinations or reoperations.

Keyword

Hyperparathyroidism; Parathyroid hormone; Parathyroidectomy; Primary hyperparathyroidism; Vitamin D deficiency

Reference

1. Rudin AV, McKenzie TJ, Wermer RA, Thompson GB, Lyden ML. Primary hyperparathyroidism: redefining cure. Am Surg. 2019; 85:214–218. PMID: 30819301.

2. Felger EA, Kandil E. Primary hyperparathyroidism. Otolaryngol Clin North Am. 2010; 43:417–432. PMID: 20510724.

3. Krawitz R, Glover A, Koneru S, Jiang J, Di Marco A, Gill AJ, et al. The significance of histologically “large normal” parathyroid glands in primary hyperparathyroidism. World J Surg. 2020; 44:1149–1155. PMID: 31773224.

4. Mallick R, Nicholson KJ, Yip L, Carty SE, McCoy KL. Factors associated with late recurrence after parathyroidectomy for primary hyperparathyroidism. Surgery. 2020; 167:160–165. PMID: 31606193.

5. Paek SH, Kim SJ, Choi JY, Lee KE. Clinical usefulness of intraoperative parathyroid hormone monitoring for primary hyperparathyroidism. Ann Surg Treat Res. 2018; 94:69–73. PMID: 29441335.

6. Grant CS, Thompson G, Farley D, van Heerden J. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience. Arch Surg. 2005; 140:472–479. PMID: 15897443.

7. Mittendorf EA, McHenry CR. Persistent parathyroid hormone elevation following curative parathyroidectomy for primary hyperparathyroidism. Arch Otolaryngol Head Neck Surg. 2002; 128:275–279. PMID: 11886343.

8. de la Plaza Llamas R, Ramia Ángel JM, Arteaga Peralta V, García Amador C, López Marcano AJ, Medina Velasco AA, et al. Elevated parathyroid hormone levels after successful parathyroidectomy for primary hyperparathyroidism: a clinical review. Eur Arch Otorhinolaryngol. 2018; 275:659–669. PMID: 29209851.

9. Nordenström E, Westerdahl J, Bergenfelz A. Long-term follow-up of patients with elevated PTH levels following successful exploration for primary hyperparathyroidism. World J Surg. 2004; 28:570–575. PMID: 15366747.

10. Mandal AK, Udelsman R. Secondary hyperparathyroidism is an expected consequence of parathyroidectomy for primary hyperparathyroidism: a prospective study. Surgery. 1998; 124:1021–1027. PMID: 9854578.

11. Tisell LE, Jansson S, Nilsson B, Lundberg PA, Lindstedt G. Transient rise in intact parathyroid hormone concentration after surgery for primary hyperparathyroidism. Br J Surg. 1996; 83:665–669. PMID: 8689214.

12. Lou I, Balentine C, Clarkson S, Schneider DF, Sippel RS, Chen H. How long should we follow patients after apparently curative parathyroidectomy? Surgery. 2017; 161:54–61. PMID: 27863779.

13. Mazotas IG, Yen TW, Doffek K, Shaker JL, Carr AA, Evans DB, et al. Persistent/recurrent primary hyperparathyroidism: does the number of abnormal glands play a role? J Surg Res. 2020; 246:335–341. PMID: 31635835.

14. Udelsman R. Approach to the patient with persistent or recurrent primary hyperparathyroidism. J Clin Endocrinol Metab. 2011; 96:2950–2958. PMID: 21976743.

15. Wang TS, Ostrower ST, Heller KS. Persistently elevated parathyroid hormone levels after parathyroid surgery. Surgery. 2005; 138:1130–1136. PMID: 16360400.

16. Carty SE, Roberts MM, Virji MA, Haywood L, Yim JH. Elevated serum parathormone level after “concise parathyroidectomy” for primary sporadic hyperparathyroidism. Surgery. 2002; 132:1086–1093. PMID: 12490859.

17. Bergenfelz A, Valdemarsson S, Tibblin S. Persistent elevated serum levels of intact parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of detrimental effects of severe parathyroid disease. Surgery. 1996; 119:624–633. PMID: 8650602.

18. Denizot A, Pucini M, Chagnaud C, Botti G, Henry JF. Normocalcemia with elevated parathyroid hormone levels after surgical treatment of primary hyperparathyroidism. Am J Surg. 2001; 182:15–19. PMID: 11532408.

19. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 1999; 107:561–567. PMID: 10625024.

20. Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res. 2002; 17 Suppl 2:N75–N80. PMID: 12412781.

21. Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond). 1987; 73:659–664. PMID: 3690980.

22. Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB, et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf). 1992; 37:17–27. PMID: 1424188.

23. Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007; 22 Suppl 2:V100–V104. PMID: 18290710.

24. Rao D, Han ZH, Phillips E, Palnitkar S, Parfitt A. Loss of calcitriol receptor expression in parathyroid adenomas: implications for pathogenesis (Abstract). J Bone Miner Res. 1997; 12:S107.

25. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest. 2006; 29:511–515. PMID: 16840828.

26. Stewart ZA, Blackford A, Somervell H, Friedman K, Garrett-Mayer E, Dackiw AP, et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery. 2005; 138:1018–1026. PMID: 16360386.

27. Dhillon KS, Cohan P, Darwin C, Van Herle A, Chopra IJ. Elevated serum parathyroid hormone concentration in eucalcemic patients after parathyroidectomy for primary hyperparathyroidism and its relationship to vitamin D profile. Metabolism. 2004; 53:1101–1106. PMID: 15334367.

28. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol. 2009; 161:189–193. PMID: 19383807.

29. Chen H, Wang TS, Yen TW, Doffek K, Krzywda E, Schaefer S, et al. Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume. Ann Surg. 2010; 252:691–695. PMID: 20881776.

30. Alhefdhi A, Schneider DF, Sippel R, Chen H. Recurrent and persistence primary hyperparathyroidism occurs more frequently in patients with double adenomas. J Surg Res. 2014; 190:198–202. PMID: 24656398.